Stock A048530 INTRON BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials iNtRON Biotechnology, Inc.

Equities

A048530

KR7048530000

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 14/05/2024 am IST 		5-day change 1st Jan Change
6,520 KRW -0.31% Intraday chart for iNtRON Biotechnology, Inc. -5.78% -25.74%
13/03 INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
15/02 Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 6,45,305 4,64,141 9,15,063 7,09,999 2,69,879 2,91,422
Enterprise Value (EV) 1 6,21,283 4,09,640 8,59,183 6,17,120 1,93,300 2,34,641
P/E ratio 37.7 x -90.9 x 75.6 x 73.1 x -23,726 x -30.1 x
Yield - - - - - 1.14%
Capitalization / Revenue 31.3 x 55.6 x 20.1 x 24.2 x 19.3 x 30.4 x
EV / Revenue 30.2 x 49.1 x 18.9 x 21.1 x 13.8 x 24.5 x
EV / EBITDA 102 x -139 x 49.6 x 53.1 x 2,204 x -171 x
EV / FCF 163 x -143 x -183 x 18.8 x -533 x -27.4 x
FCF Yield 0.61% -0.7% -0.55% 5.31% -0.19% -3.65%
Price to Book 8.3 x 7.25 x 10.7 x 7.01 x 2.54 x 3.01 x
Nbr of stocks (in thousands) 29,945 29,945 32,857 33,729 33,195 33,192
Reference price 2 21,550 15,500 27,850 21,050 8,130 8,780
Announcement Date 19/03/19 18/03/20 17/03/21 16/03/22 20/03/23 13/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 20,584 8,347 45,433 29,308 14,007 9,585
EBITDA 1 6,106 -2,945 17,305 11,614 87.7 -1,373
EBIT 1 5,166 -4,368 15,736 10,077 -1,479 -3,285
Operating Margin 25.1% -52.33% 34.64% 34.38% -10.56% -34.27%
Earnings before Tax (EBT) 1 7,312 -1,915 17,051 10,575 8,319 -10,837
Net income 1 8,711 -3,187 14,948 9,728 5,712 -9,695
Net margin 42.32% -38.18% 32.9% 33.19% 40.78% -101.15%
EPS 2 571.0 -170.5 368.2 288.0 -0.3427 -292.1
Free Cash Flow 1 3,810 -2,857 -4,705 32,785 -362.7 -8,555
FCF margin 18.51% -34.23% -10.36% 111.86% -2.59% -89.25%
FCF Conversion (EBITDA) 62.39% - - 282.29% - -
FCF Conversion (Net income) 43.73% - - 337.02% - -
Dividend per Share - - - - - 100.0
Announcement Date 19/03/19 18/03/20 17/03/21 16/03/22 20/03/23 13/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q2 2022 Q3 2023 Q3
Net sales 1 2.733 2.829 1.671
EBITDA - - -
EBIT -1.518 -0.4623 -
Operating Margin -55.55% -16.34% -
Earnings before Tax (EBT) - - -
Net income - - -
Net margin - - -
EPS - - -
Dividend per Share - - -
Announcement Date 16/08/22 14/11/22 14/11/23
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 24,023 54,501 55,881 92,880 76,580 56,781
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 3,810 -2,857 -4,705 32,785 -363 -8,555
ROE (net income / shareholders' equity) 25.1% -6.12% 19.9% 10.4% 5.5% -9.56%
ROA (Net income/ Total Assets) 6.43% -3.8% 10.4% 4.96% -0.63% -1.71%
Assets 1 1,35,475 83,956 1,44,059 1,96,078 -9,09,395 5,65,693
Book Value Per Share 2 2,597 2,137 2,595 3,005 3,199 2,914
Cash Flow per Share 2 1,411 1,781 1,824 2,229 778.0 1,235
Capex 1 551 300 4,852 3,046 2,229 7,791
Capex / Sales 2.67% 3.6% 10.68% 10.39% 15.91% 81.28%
Announcement Date 19/03/19 18/03/20 17/03/21 16/03/22 20/03/23 13/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INTRON BIOTECHNOLOGY, INC. Stock iNtRON Biotechnology, Inc.
-25.74% 159M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.48% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.26% 106B
BIONTECH SE Stock BioNTech SE
-12.55% 22.24B
ARGENX SE Stock argenx SE
+0.44% 21.25B
GENMAB A/S Stock Genmab A/S
-4.18% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.62% 16.81B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.32% 12.54B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.36% 8.09B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A048530 Stock
  4. Financials iNtRON Biotechnology, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW